A manufacturer of devices intended to test lead levels in blood has agreed to plead guilty to misbranding charges, pay $42 million, and enter into a deferred prosecution agreement resolving felony conspiracy charges in connection with the firm’s alleged multiyear concealment of widespread device malfunctions from the FDA and the company’s customers (United States v. Magellan D... Read More